Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

References

• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383:2603–2615.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2020;397:99–111.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383:1920–1931.
   PubMed Web of Science ®Google Scholar
• Implications of the Emerging SARS-CoV-2 Variant VOC 202012/01.
   Google Scholar
• Davies NG, Barnard RC, Jarvis CI, et al. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of concern 202012/01 in england. MedRxiv. 2020.
   Google Scholar
• Widge AT, Rouphael NG, Jackson LA, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2020;384:80–82.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet. 2020;396:1979–1993.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2020;21:39–51.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama. 2020;324:1–10.
   Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320–2332.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020;21:181–192.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21:39–51.
   PubMed Web of Science ®Google Scholar
• Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials. medRxiv. 2020;396:479–488.
   Google Scholar
• Zhu F-C, Guan X-H, Li Y-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479–488.
   PubMed Web of Science ®Google Scholar
• Dagotto G, Yu J, Barouch DH. Approaches and challenges in SARS-CoV-2 vaccine development. Cell Host Microbe. 2020;28:364–370.
   PubMed Web of Science ®Google Scholar
• Excler JL, Kim JH. Novel prime-boost vaccine strategies against HIV-1. Expert Rev Vaccines. 2019;18:765–779.
   PubMed Web of Science ®Google Scholar
• Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009;21:34651.
   Web of Science ®Google Scholar
• Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9:680–686.
   PubMed Web of Science ®Google Scholar
• McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2020;590:630–634.
   Web of Science ®Google Scholar
• Wang S, Parker C, Taaffe J, et al. Heterologous HA DNA vaccine prime–inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine. 2008;26:3626–3633.
   PubMed Web of Science ®Google Scholar
• Gil A, Shen S, Coley S, et al. DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus. Hum Vaccin Immunother. 2013;9:2120–2132.
   Web of Science ®Google Scholar
• Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19. N Engl J Med. 2020;384:229–237.
   Web of Science ®Google Scholar
• Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020;11:4704.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384:403–416.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–2450.
   PubMed Web of Science ®Google Scholar
• Diamond MS, Pierson TC. Molecular insight into dengue virus pathogenesis and Its Implications for disease control. Cell. 2015;162:488–492.
   PubMed Web of Science ®Google Scholar
• Lee WS, Wheatley AK, Kent SJ, et al. Antibody-dependent enhancement and SARSCoV-2 vaccines and therapies. Nature Microbiology. 2020;5:1185–1191.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from russia. Lancet. 2020;396:887–897.
   PubMed Web of Science ®Google Scholar
• Hollister K, Chen Y, Wang S, et al. The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination. Hum Vaccin Immunother. 2014;10:1985–1992.
   PubMed Web of Science ®Google Scholar
• Qi H, Chen X, Chu C, et al. Tfh cell differentiation and their function in promoting B-cell responses. Adv Exp Med Biol. 2014;841:15380.
   Web of Science ®Google Scholar
• Law H, Venturi V, Kelleher A, et al. Tfh cells in health and immunity: potential targets for systems biology Approaches to vaccination. Int J Mol Sci. 2020;21:8524.
   Web of Science ®Google Scholar
• Wang S, Arthos J, Lawrence JM, et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming To generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol. 2005;79:7933–7937.
   PubMed Web of Science ®Google Scholar